EGFR and cancer: Based on the tight tangling between uPAR signaling and cancer, JAK inhibitors might be potential anti-cancer repurposing drugs when used in combination with chemotherapy, radiotherapy, immunotherapy or other targeted agents (e.g., the EGFR inhibitor Erlotinib) [51].